Diabetes Trials Unit
Tel: 01865 857240
Rury Holman trained in medicine at the University of Bristol in the United Kingdom, founded the University of Oxford Diabetes Trials Unit (DTU) in 1985, and was appointed as the first Professor of Diabetic Medicine at the University of Oxford in 1998. He runs an active Translational Research Group undertaking investigator-led early phase trials of novel therapeutic agents, new medical devices and complex interventions. He also designs and runs investigator-led global cardiovascular outcome trials and is currently joint Chair of EXSCEL and TECOS, and Chief Investigator of ACE and UKPDS. In addition, has a major interest in risk prediction and has co-produced the UKPDS Risk Engine and the UKPDS Outcomes Model, which is used by NICE to assess the potential impact of antidiabetic therapies. Professor Holman has received 16 national and international awards and has published over 370 peer-reviewed papers that have been cited more than 66,000 times.
Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus
Carlos E Barbery et al.
Am Heart J. 2021;239:59-63
Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
Moritz J. Hundertmark et al.
ESC Heart Failure 2021;8:2580-2590
Increased Risk of Incident Heart Failure and Death is Associated with Insulin Resistance in People with Newly- Diagnosed Type 2 Diabetes: UKPDS 89
Malgorzata Wamil et al.
Diabetes Care 2021;44:1-8
Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90)
Jose Leal et al.
Diabet Med. 2021
Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88
Marcus Lind et al.
Diabetes Care 2021
Neck circumference and waist circumference associated with cardiovascular events in type 2 diabetes (Beijing Community Diabetes Study 23)
Guang Ran Yang et al.
Sci Rep. 2021;11:9491